CSL News: CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) P - 7th Oct 2022, 3:00am

[annb0t]

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government's pandemic preparedness activities Third influenza pandemic preparedness award to CSL Seqirus under a multi-year agreement with Biomedical Advanced Research and Development Authority (BARDA)

SUMMIT, N.J., Oct. 6, 2022 /PRNewswire/ -- CSL Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that t...

>>> Read more: CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine